Viking Therapeutics, Inc. - Common Stock (VKTX)

While we wait for the earnings report to be posted along with the forward guidance predictions, the chart looks interesting. 

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles.

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill.

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

Pfizer bows, but is not entirely out of the GLP-1 race.

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

The company is continuing to test a daily pill that blocks GIPR.

Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver.

The "rapid" enrollment suggests there's still huge interest in the company's approach to obesity treatment.

Stocks gained after the Fed meeting but drifted lower after disappointing guidance from FedEx; next week's inflation data is unlikely to provide needed clarity